Study Presented at SABCS 2025 Demonstrates Identification of Low Risk Luminal Breast Cancer Patients Using MammaTyper®
Low Risk Patients Identified by MammaTyper® LRP Had Significantly Better DDFS and Did Not Benefit from Adjuvant Chemotherapy BERLIN, GERMANY, December 15, 2025 /EINPresswire.com/ -- Cerca Biotech., a Germany-based diagnostics company, announces the …